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An important feature of glucose homeostasis is the
effective release of glucagon from the pancreatic
a cell. The molecular mechanisms regulating gluca-
gon secretion are still poorly understood. We now
demonstrate that human a cells express ionotropic
glutamate receptors (iGluRs) that are essential for
glucagon release. A lowering in glucose concentra-
tion results in the release of glutamate from the
a cell. Glutamate then acts on iGluRs of the AMPA/
kainate type, resulting in membrane depolarization,
opening of voltage-gated Ca2+ channels, increase
in cytoplasmic free Ca2+ concentration, and en-
hanced glucagon release. In vivo blockade of iGluRs
reduces glucagon secretion and exacerbates insulin-
induced hypoglycemia inmice. Hence, the glutamate
autocrine feedback loop endows the a cell with the
ability to effectively potentiate its own secretory ac-
tivity. This is a prerequisite to guarantee adequate
glucagon release despite relatively modest changes
in blood glucose concentration under physiological
conditions.
INTRODUCTION
Blood glucose homeostasis is controlled by the concerted
secretion of pancreatic hormones from the various cell types in
the endocrine part of the pancreas, the islets of Langerhans.
The secretion of insulin and glucagon from the pancreatic
b and a cells, respectively, is regulated by nutrients as well as
by autocrine, paracrine, and nervous signals. Whereas the mo-
lecular mechanisms involved in insulin secretion are relatively
well understood, those regulating glucagon secretion are not
clear. A pivotal question is how glucagon can be so effectively
released subsequent to the modest changes in blood glucose
concentration prevailing under normal conditions.
Secretion of glucagon from a cells is increased when the blood
glucose concentration decreases (Unger, 1985; Zhou et al.,
2004), but the exact underlying molecular mechanisms that act
on the a cell to induce glucagon release are not known. It hasbeen proposed that high glucose levels suppress glucagon
release by acting directly on a cells (Gopel et al., 2000; Unger,
1985). Mechanistically this has been explained by the selective
expression of voltage-sensitive Na+ channels in a cells that con-
tribute to the generation of neuronal-like action potentials that
are inactivated by prolonged cell membrane depolarization
(Gopel et al., 2000). According to this model, the inactivation of
these Na+ channels suppresses a cell activity when glucose
levels are high. Other studies, however, have shown that glucose
activates a cells by mechanisms that mirror stimulus-secretion
coupling in b cells—that is, glucose stimulates a cells and b cells
alike (Olsen et al., 2005; Wendt et al., 2004). Therefore, inhibitory
paracrine signals such as insulin, GABA, and Zn2+ being
released from the b cell, rather than changes in the glucose
concentration per se, have been suggested to be involved in
the direct regulation of glucagon release (Franklin et al., 2005;
Gromada et al., 2007; Ishihara et al., 2003; Kisanuki et al.,
1995; Ravier and Rutter, 2005; Rorsman et al., 1989).
However, a relief of inhibitory paracrine signals cannot fully
explain how relatively minor decreases in glucose concentration
so effectively promote glucagon release. Therefore, we hypoth-
esized that a cells require positive feedback loops to produce
a full glucagon response (see also Hayashi et al., 2003b). Gluta-
mate, a major excitatory neurotransmitter in the central nervous
system, is of special interest because, unlike most other signals,
it may stimulate rather than inhibit glucagon secretion in the islet
(Bertrand et al., 1993; Hayashi et al., 2003c). Vesicular glutamate
transporters that facilitate glutamate uptake into vesicles are
expressed by a cells (Hayashi et al., 2001), and glutamate is
secreted together with glucagon (Hayashi et al., 2003c).
Unfortunately, studies based in rodents have shown a large
complexity in glutamate signaling in the islet (Moriyama and
Hayashi, 2003). Results so far are conflicting, and the role of glu-
tamate remains enigmatic. For instance, it has been reported
that glutamate stimulates glucagon secretion via ionotropic glu-
tamate receptors (iGluRs) (Bertrand et al., 1993), that it inhibits
glucagon secretion via metabotropic glutamate receptors
(mGluRs) (Uehara et al., 2004), and that it activates mGluRs
and iGluRs in b cells to increase insulin secretion (Bertrand
et al., 1992, 1995; Storto et al., 2006). To resolve this contro-
versy, we have therefore systematically used several molecular
and physiological techniques to define the role of glutamate
signaling in human, monkey, and mouse islets of Langerhans.Cell Metabolism 7, 545–554, June 2008 ª2008 Elsevier Inc. 545
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Activation of iGluRs Induces Glucagon Secretion
By performing RT-PCR on isolated human and monkey islets, we
could detect transcripts for the iGluR subunits GluR1, GluR2,
GluR3, and GluR4 of the AMPA receptor type and GluR5,
GluR6, GluR7, and KA2 of the kainate receptor type (data not
shown). These results are in agreement with those published
in the Beta Cell Biology Consortium database (http://www.
betacell.org/resources/data/epcondb/). The expression of iGluR
subunits in islets was confirmed by immunoblot analysis with an-
tibodies against GluR2/3 (data not shown). GluR1 and GluR4
subunits could not be detected. The bands of the correct size
disappeared from the immunoblots when the GluR2/3 antibody
was preadsorbed, but the immunostaining in pancreas sections
did not, indicating that the immunofluorescent signal obtained
with the GluR2/3 antibodies was not specific. To study cell-spe-
cific expression of iGluRs, we thus decided to use alternative
techniques (see below).
In contrast to previous results in rodent islets (Moriyama and
Hayashi, 2003), we found that functional AMPA/kainate iGluRs
were present exclusively in a cells of human and monkey islets
(Figure 1 and Figure 2). By using the in vitro perifusion technique
to detect hormone secretion, we determined that glutamate
Figure 1. Activationof IonotropicGlutamate
Receptors in Human Islets Induces Gluca-
gon Secretion
(A) Glutamate induced glucagon responses that
could be blocked by CNQX (10 mM). Kainate and
AMPA (both 100 mM) also elicited strong glucagon
secretion.
(B) Quantification of results in (A) (n = 5 islet prep-
arations).
(C) The metabotropic glutamate receptor antago-
nist CPPG (100 mM) did not affect the glutamate-
induced glucagon response. The metabotropic
glutamate receptor agonists trans-ACPD (tACPD;
100 mM) and ACPT-1 (100 mM) did not elicit
changes in glucagon secretion.
(D) Quantification of results in (C) (n = 3 islet prep-
arations).
(E) Insulin release was induced by high glucose
(11 mM, 11G) but not by kainate (representative
of six islet preparations).
(F) Glutamate elicited concentration-dependent
[Ca2+]i responses in human islets (n = 4 islet prep-
arations). Data were curve fitted using the Hill
equation.
Results are shown as mean ± SEM.
(1 mM–1 mM) stimulated large, concentra-
tion-dependent increases in glucagon re-
lease (Figures 1A and 1B). Increases in
glucagon release could also be elicited
by the iGluR agonists kainate (100 mM)
and AMPA (100 mM; Figures 1A and 1B).
CNQX (10 mM) and DNQX (10 mM; data
not shown), two antagonists for iGluRs
of the AMPA/kainate type, inhibited gluta-
mate-induced glucagon release by more
than 90% (Figures 1A and 1B). Metabotropic receptors have
been reported to mediate negative autocrine effect on glucagon
secretion in rat islets (Uehara et al., 2004). Using human islets,
however, we found that the metabotropic receptor agonists
trans-ACPD (100mM) and ACPT-1 (100mM) and the metabotropic
antagonist CPPG (100 mM) did not affect basal glucagon secre-
tion or glucagon responses to glutamate (Figures 1C and 1D).
Neither kainate (100 mM), glutamate (100 mM), nor AMPA
(100 mM) stimulated increases in insulin release in human
(Figure 1E) and monkey (data not shown) islets. These effects
of iGluRs agonists were similar at all glucose concentrations
tested (1 mM, 3 mM, and 11 mM).
a Cells Express Functional iGluRs
of the AMPA/Kainate Type
Human and monkey islets as well as dispersed single islet cells
loaded with the Ca2+ indicator Fura-2 showed increases in
cytoplasmic free Ca2+ concentration ([Ca2+]i) in response to glu-
tamate (100 mM). [Ca2+]i responses to glutamate were concen-
tration dependent (Figure 1F) and could be blocked by CNQX
(10 mM) (see below). The range of glutamate concentrations
that elicited [Ca2+]i responses was similar to that reported for
neurons in the central nervous system (Hollmann and Heine-
mann, 1994; Seeburg, 1993). Cells that responded to glutamate546 Cell Metabolism 7, 545–554, June 2008 ª2008 Elsevier Inc.
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(n = 12 of 12 cells). Cells that responded to glutamate in terms of
increases in [Ca2+]i did not respond to high glucose concentra-
tions (11 mM; n = 43 of 43 cells; Figure 2A), and cells that re-
sponded to high glucose did not respond to glutamate (n = 64
of 64 cells; Figure 2A). Using immunofluorescence after [Ca2+]i
imaging, we found that most glutamate-responsive cells were
glucagon immunoreactive (n = 34 of 37 cells; n = 4 human prep-
arations; Figure 2A). None of the insulin-immunoreactive cells
responded to kainate (n = 8 of 8), but most of the glucagon-im-
Figure 2. a Cells in Human Pancreatic Islets Express Functional
Ionotropic Glutamate Receptors of the AMPA/Kainate Type
(A) Top row: three sequential images showing [Ca2+]i responses to 3 mM
glucose (3G), 11 mM glucose (11G), and 100 mM glutamate in dispersed
human islet cells (pseudocolor scale). Bottom left: glucagon (green) and insulin
(red) immunostaining. Glucagon-immunoreactive cells 2 and 3 responded to
glutamate but not to 11G. Insulin-immunoreactive cells 1 and 4 responded
to 11G but not to glutamate. Bottom right: traces of the [Ca2+]i responses of
these cells. Arrows indicate the time points at which the images were taken.
Bars under traces indicate stimulus application. Scale bar = 50 mm. 1G = 1 mM
glucose. Results are representative of four human islet preparations.
(B) Gene expression profiling of individual a cells (left) and b cells (right) from
human (red circles) and monkey (black circles) islets. Each row represents
a single cell; each column represents a different glutamate receptor gene.
Black or red circles denote that RT-PCR products were detected.munoreactive cells did (n = 7 of 9). Similar results were obtained
with monkey islets (data not shown).
Single-cell RT-PCR experiments showed that transcripts
for the AMPA/kainate genes GRIA2, GRIA3, and GRIK2
(Figure 2B) could be detected consistently in cells identified as
a cells (positive for glucagon but not insulin, somatostatin, or
pancreatic polypeptide; n = 7 human cells, n = 5 monkey cells).
By contrast, in identified b cells (positive for insulin only) we could
not detect transcripts for AMPA/kainate genes (Figure 2B). Tran-
scripts for the metabotropic glutamate receptor 4 gene (GRM4)
were found in 2 of 7 human a cells, but not in monkey a cells
or in b cells of either species (Figure 2B). None of the examined
cells contained transcripts for the metabotropic glutamate
receptor 5 gene (GRM5). These data indicate that human and
monkey a cells, but not b cells, express functional iGluRs of
the AMPA/kainate type.
Effects Induced by AMPA/Kainate Receptor Activation
How does activation of AMPA/kainate iGluRs lead to glucagon
secretion? Whole-cell patch-clamp recordings on isolated
human islet cells showed that application of kainate (100 mM) eli-
cited inward currents that could be blocked by NBQX (10 mM), an
AMPA/kainate receptor antagonist (Figure 3A). [Ca2+]i responses
to kainate were blocked by CNQX (10 mM) and were abolished in
the absence of extracellular Ca2+ and by La3+ (30 mM), a potent
blocker of voltage-gated Ca2+ channels (Figures 3C and 3D).
The L-type Ca2+ channel blocker nifedipine (10 mM) reduced kai-
nate-induced [Ca2+]i responses by60% (Figure 3D). We further
investigated whether these mechanisms are involved in kainate-
induced glucagon secretion. Using perifusion assays to detect
hormone secretion, we found that kainate-stimulated glucagon
secretion was abolished in the absence of extracellular Ca2+
(Figure 3B). La3+ (30 mM) and a combination of selective Ca2+
channel inhibitors greatly diminished (>90%) the glucagon re-
sponse to kainate. These results indicate that kainate elicited
glucagon secretion by activating inward currents through
AMPA/kainate iGluRs (Hollmann and Heinemann, 1994; Mayer
and Armstrong, 2004), which depolarize the a cell plasma
membrane, resulting in Ca2+ influx through voltage-gated Ca2+
channels and consequently an increase in [Ca2+]i.
Primate a Cells Secrete Glutamate
There are several putative sources of glutamate in islets, e.g.,
nerve terminals and endocrine cells. We therefore investigated
whether glutamate is released from the glucagon-containing
a cells. Cells capable of vesicular release of glutamate express
vesicular glutamate transporters (vGluTs; Fremeau et al.,
2004). Our RT-PCR results indicated that primate islets express
vGluT1 and vGluT2 (data not shown). To investigate the localiza-
tion of vGluTs in primate islets, we performed multiple immunos-
taining on human and monkey pancreatic sections (Figure 4A). In
line with previous studies in rat (Hayashi et al., 2003a, 2003b), we
found that a cells, but not insulin-containing b cells, were immu-
noreactive for vGluT1 (Figure 4A). These results suggest that
a cells are a major source of glutamate within the primate islet.
To visualize glutamate release directly, we adapted an
enzymatic assay for microfluorometric detection of extracellular
glutamate (Akagi et al., 2003) and performed this assay
using isolated cultured islets (Figure 4B). When the glucoseCell Metabolism 7, 545–554, June 2008 ª2008 Elsevier Inc. 547
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Require Ca2+ Influx through Voltage-
Dependent Ca2+ Channels
(A) Activation of ionotropic glutamate receptors
(iGluRs) elicits inward currents in human islet cells.
Top left: a representative whole-cell current
evoked by kainate (100 mM). Bottom left: the kai-
nate-evoked current could be blocked with the
AMPA/kainate receptor antagonist NBQX (10 mM).
Right: the amplitudes of these currents averaged
for four cells. Holding potential = 70 mV. Bars
over current traces indicate kainate application.
(B) Perifusion assays show that kainate (100 mM)
stimulated large increases in glucagon secretion
(left) that were abolished in the absence of extra-
cellular Ca2+ (0 Ca2+ + 1 mM EGTA) and strongly
diminished in the presence of the Ca2+ channel
blocker La3+ (30 mM) or a combination of the spe-
cific Ca2+ channel inhibitors nimodipine (10 mM),
conotoxin GVIA (1 mM), agatoxin IVA (0.1 mM),
and mibefradil (1 mM). Average traces are shown
(n = 3 human islet preparations). Arrow indicates
switch to new solution.
(C) An averaged trace (n = 9 cells; three monkey is-
let preparations) showing that [Ca2+]i responses to
kainate were abolished at nominal 0 Ca2+.
(D) [Ca2+]i responses to kainate were inhibited by
CNQX (10 mM, n = 7 cells) and the Ca2+ channel
blockers La3+ (30 mM, n = 14 cells) and nifedipine
(10 mM, n = 18 cells). Shown are the means of the peak amplitudes of the [Ca2+]i responses (changes in the 340/380 fluorescence emission ratio) to kainate.
Data are from three separate monkey islet preparations. *p < 0.05 by Student’s t test.
Error bars represent ±SEM.concentration was lowered from 6 mM to 1 mM, fluorescence
intensity increased significantly, indicating that glutamate was
released (Figures 4C and 4D). By contrast, stimulation with
high glucose concentrations (11 mM) did not induce glutamate
secretion (Figures 4C and 4D). When stimulated with kainate
(100 mM), a stimulus specific for a cells (see above), islets
strongly released glutamate (Figures 4B–4D). KCl (30 mM) depo-
larization also elicited large increases in glutamate release
(Figure 4D). Fluorescent signals were small in the absence of
the glutamate-sensitive enzyme glutamate oxidase (Figures
4B–4D), indicating that the large increases in fluorescence inten-
sity in this assay depended on the release of glutamate.
To determine whether neuronal elements could contribute to
the glutamate signal, we examined isolated islets for the pres-
ence of the neuronal markers synapsin, neuron-specific enolase,
neurofilament 200, and neurofilament H. We found few if any
labeled fibers, boutons, or cells (data not shown), in agreement
with a previous study showing that very few nerve terminals
survive overnight islet culture (Karlsson et al., 1997). Because
we performed our experiments using cultured islets, we con-
clude that intraislet glutamate is mainly derived from stimulated
primate a cells.
Glutamate Signaling Provides Positive Feedback
for Glucagon Secretion
Our results indicate that a cells express iGluRs and secrete gluta-
mate, suggesting that glutamate is an autocrine signal. We hy-
pothesized that a decrease in glucose concentration activates
a glutamate feedback loop that potentiates glucagon secretion.
If so, applying an iGluR antagonist should reduce the glucagon548 Cell Metabolism 7, 545–554, June 2008 ª2008 Elsevier Inc.response. Instead of testing this hypothesis with perifusion as-
says, which may not be sufficiently sensitive to detect responses
to low concentrations of glucose (Hope et al., 2004), we decided
to use a more sensitive assay, namely detection of glucagon re-
lease by biosensor cells. We placed human islets on a layer of bio-
sensor cells expressing glucagon receptors (see Experimental
Procedures) (EC50 for glucagon = 30 pM) (Figure 5A). The biosen-
sor cells express cyclic nucleotide-gated channels, which are
activated by elevated intracellular levels of cAMP subsequent
to stimulation of the glucagon receptors, resulting in membrane
depolarization and Ca2+ influx. Glucagon release from islets
was monitored in real time by recording [Ca2+]i responses from
the biosensor cells loaded with the [Ca2+]i indicator Fura-2. In
the absence of islets, biosensor cells did not respond to gluta-
mate (100 mM) (Figure 5B) or a change in glucose concentrations
(data not shown). When human islets were placed on the biosen-
sor cells, the biosensor cells showed large [Ca2+]i responses to
glutamate application (Figure 5B), indicating that glucagon re-
lease was induced. Lowering the glucose concentration from
6 mM to 1 mM also induced glucagon release as measured by
the [Ca2+]i responses in biosensor cells (Figure 5C). The glucagon
response to decreasing the glucose concentration was inhibited
by CNQX (10 mM) (54% reduction; Figure 5D). Hence, we con-
clude that activation of iGluRs on a cells is necessary for prompt
glucagon secretion when glucose concentration decreases.
iGluRs on a Cells Contribute to In Vivo
Glucose Homeostasis
We have found that activation of AMPA/kainate receptors is
among the strongest stimuli for glucagon secretion in vitro. To
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in vivo glucose homeostasis, we performed experiments in mice.
Mouse islets in vitro secreted glucagon, not insulin, in response
to AMPA/kainate iGluR activation (Figures 6A and 6D). The me-
tabotropic receptor agonists trans-ACPD (100 mM) and ACPT-1
(100 mM) and the metabotropic receptor antagonist CPPG
(100 mM) did not affect basal or glutamate-induced glucagon
secretion (Figure 6B). Moreover, glucagon responses to gluta-
mate were indistinguishable in islets from wild-type and mGluR4
knockout mice (Figure 6C). Therefore, mouse a cells, but not
b cells, responded to glutamate mainly via activation of iGluRs.
These results indicate that glutamate signaling in mouse islets
is similar to that in human islets.
To determine whether in vivo activation of AMPA/kainate
receptors affects glucagon secretion, we injected mice with glu-
tamate and the AMPA receptor-specific agonist AMPA. Mice
injected intraperitoneally (i.p.) with glutamate (30 mg/kg i.p.)
Figure 4. Stimulated Primate a Cells Release Glutamate
(A) Confocal images of a monkey pancreatic section containing an islet. Im-
munoreactivity for the vesicular glutamate transporter 1 (vGluT1) colocalized
with glucagon but not insulin immunostaining. Results are representative of
three human pancreata. Scale bar = 20 mm.
(B) Representative images of islets in experiments using a fluorescent enzy-
matic assay to detect glutamate release. In this assay, released glutamate is
a substrate in an enzymatic chain reaction that generates the fluorescent prod-
uct resorufin. Resorufin fluorescence is color coded; an increase from low
(blue, rest) to high (yellow, kainate) indicates increased glutamate release in
response to kainate. There was no fluorescence increase in the absence of
the enzyme glutamate oxidase (GO, bottom panel). Scale bar = 50 mm.
(C and D) In the absence of the enzyme glutamate oxidase (GO), application
of kainate and KCl did not increase resorufin fluorescence. Low glucose
(1 mM, 1G; p = 0.005), kainate (100 mM, kain; p < 0.001), and KCl (30 mM;
p < 0.001) depolarization, but not high glucose (11 mM, 11G; p = 0.289),
induced significant glutamate release from islets as compared to kainate
without GO (GO; n = 3 monkey islet preparations; one-way ANOVA followed
by multiple-comparisons procedure by Student-Newman-Keuls method).
a.u. = arbitrary units. Results in (D) are presented as mean ± SEM.and AMPA (15 mg/kg i.p.) showed increased plasma glucagon
concentrations at 30 min after treatment (Figure 7A). Plasma in-
sulin concentrations were not affected. Concomitantly, these
mice had increased glucose levels (Figure 7A), which should
be the result of the increased glucagon secretion. Glutamate
and AMPA most likely did not have central effects because
glutamate does not penetrate the blood-brain barrier (Beyr-
euther et al., 2007) and, at the concentrations used, AMPA did
not induce convulsions indicative of central nervous system pen-
etration (Arnt et al., 1995). Although we cannot rule out effects on
peripheral neurons, the collective interpretation of our results
strongly suggests that we indeed directly activated AMPA/kai-
nate receptors on a cells and thereby stimulated glucagon
secretion in mice in vivo.
Increased glucagon secretion from a cells in the endocrine
pancreas plays a primary role in glucose counterregulation
(Banarer et al., 2002; Rizza et al., 1979). We investigated whether
a cells require positive glutamate feedback loops to produce
a full glucagon response to a lowering in glucose concentration.
In the initial experiments, mice were injected with insulin
(1.5 U/kg i.p.) to induce hypoglycemia. In these mice, systemic
treatment with the AMPA/kainate iGluR antagonist NBQX
(20 mg/kg i.p.) increased the insulin-induced drop in plasma
Figure 5. A Stimulatory Autocrine Glutamate Feedback Loop Is
Needed for Effective Glucagon Release
(A) Illustration of the experimental approach used to measure islet glucagon
secretion in real time using glucagon-sensitive biosensor cells.
(B) Exogenous glutamate elicited glucagon secretion from human islets as
measured by [Ca2+]i responses in individual glucagon biosensor cells (traces
at left). No responses were seen in the glucagon biosensor cells in the absence
of human islets (traces at right).
(C) Lowering the glucose concentration from 6 mM to 1 mM (arrow) induced
glucagon secretion as measured by [Ca2+]i responses in biosensor cells
(n = 6 regions of interest). Rinsing caused an abrupt decrease in [Ca2+]i in
biosensor cells. Results in (C) and (D) are presented as mean ± SEM.
(D) Quantification of the data in (C) shows that the AMPA/kainate iGluR antag-
onist CNQX (10 mM) significantly inhibited the effect of glucose lowering on
glucagon release by 54% (measured 8 min after reducing the glucose concen-
tration; n = 3 islet preparations; *p = 0.042 by Student’s t test).Cell Metabolism 7, 545–554, June 2008 ª2008 Elsevier Inc. 549
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Islets Is Similar to that in Primate Islets
(A) Left: perifusion assays of mouse islets showed
that glutamate (100 mM) stimulated glucagon re-
lease that was blocked by DNQX (10 mM) (n = 6
perifusions). Right: kainate and AMPA (both
100 mM) also stimulated glucagon secretion (n = 3
perifusions).
(B) Left: the metabotropic glutamate receptor
agonists tACPD (100 mM) and ACPT-1 (100 mM)
did not elicit changes in glucagon secretion. Right:
the metabotropic glutamate receptor antagonist
CPPG (100 mM) did not affect the glutamate-
induced glucagon response (n = 3 perifusions).
(C) Glucagon responses to glutamate (100 mM) in
islets from mice lacking the metabotropic gluta-
mate receptor mGluR4 were not different from
those of islets from control mice (n = 4 islet prepa-
rations per group).
(D) Insulin release was induced by high glucose
(11 mM, 11G) but not by kainate (left) or by AMPA
or glutamate (right) (n = 3 islet preparations).
Results are presented as mean ± SEM.glucose levels (data not shown). At this concentration, NBQX did
not cause sedation, suggesting that the treatment impaired glu-
cose counterregulation without central effects on autonomic
functions (Lees, 2000).
To examine whether blocking AMPA/kainate receptors dimin-
ishes the counterregulatory response to systemic hypoglycemia,
we used the hyperinsulinemic-hypoglycemic clamp technique
(Figure 7B). This technique provides a standardized hypoglyce-
mic stimulus whereby plasma glucose concentrations can be
held at a desired level of glycemia (3 mM in our study). Mice
treated systemically with the AMPA/kainate iGluR antagonist
NBQX (10 mg/kg intravenous; n = 7) needed larger infusion rates
of glucose to maintain the desired level of glycemia, suggesting
that, compared to control, saline-injected mice (n = 5), their
counterregulatory response was diminished (Figure 7C). Indeed,
we found that plasma glucagon levels were lower in NBQX-
treated mice, indicating that activation of iGluRs is needed
for efficient glucagon secretion in response to hypoglycemia
(Figure 7B).
DISCUSSION
Our results firmly establish glutamate as a bona fide autocrine
signaling molecule in a cells providing positive feedback for
glucagon secretion in human islets. We found that glutamate is
secreted by a cells and that a cells, not b cells, express iGluRs
of the AMPA/kainate type. Activation of these receptors by
a cell-derived glutamate generates positive feedback for a cell
function and amplifies glucagon secretion. This autocrine signal-
ing pathway helps explain how a modest decrease in blood glu-
cose concentration effectively induces glucagon release from
the pancreatic a cell.550 Cell Metabolism 7, 545–554, June 2008 ª2008 Elsevier Inc.Our results demonstrating that glutamate provides a positive
feedback for glucagon release are in agreement with studies
showing that glutamate stimulates glucagon secretion (Bertrand
et al., 1993) but contrast with reports suggesting that the effect
of glutamate is inhibitory and mediated by mGluR4 receptors
(Moriyama and Hayashi, 2003). Glutamate was excitatory in all
of our physiological experiments (e.g., [Ca2+]i imaging, dynamic
hormone secretion assays, and in vivo plasma glucagon detec-
tion), and responses could be blocked by AMPA/kainate recep-
tor antagonists, indicating that stimulation of glucagon release
via iGluRs is the predominant effect of the glutamate autocrine
feedback loop. Our findings showing that agonists and antago-
nists for metabotropic glutamate receptors did not affect gluca-
gon secretion demonstrate that these receptors are not involved
in glutamate signaling in human a cells. Because glucagon re-
sponses to glutamate were not altered in mice lacking mGluR4
receptors, we further conclude that this receptor likely does
not contribute to a cell responses to glutamate as suggested
previously (Uehara et al., 2004).
In contrast with previous results in rodents (Gonoi et al., 1994;
Inagaki et al., 1995; Moriyama and Hayashi, 2003; Weaver et al.,
1996), we could not find evidence for iGluRs in b cells in any of
the three species examined. The discrepancies with our results
may be explained by species differences and the use of different
methods. It is important to note, however, that immunofluores-
cence studies have so far provided most of the evidence for
localization of iGluRs in b cells (Muroyama et al., 2004; Weaver
et al., 1996). These studies have not been verified with in situ
hybridization or single-cell RT-PCR. It is therefore difficult to as-
certain whether the reported immunostaining patterns represent
iGluRs in b cells, particularly given that immunohistochemistry
can yield spurious results (Saper and Sawchenko, 2003). In our
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Stimulates Glucagon Secretion
(A) Left: mice treated systemically with glutamate
(30 mg/kg i.p.; n = 7 mice) or AMPA (15 mg/kg
i.p.; n = 8 mice) showed increased plasma gluca-
gon concentrations (*p < 0.05 by ANOVA). Middle:
plasma insulin concentrations did not change.
Right: 30 min after AMPA injection, AMPA-treated
mice showed increased plasma glucose concen-
trations (d, n = 8 mice; *p < 0.05 by Student’s
t test) as compared to PBS-injected mice (B,
n = 4 mice). Results in (A)–(C) are presented as
mean ± SEM.
(B) Hyperinsulinemic-hypoglycemic clamp to pro-
vide a constant hypoglycemic stimulus at a blood
glucose concentration of 3 mM (left) was in-
duced with insulin infusion (middle). Glucagon se-
cretion in response to hypoglycemia was signifi-
cantly diminished in mice after NBQX infusion
(right) (10 mg/kg; red circles, n = 7) compared
with saline-infused mice (black circles, n = 5;
*p < 0.05 by repeated-measures ANOVA). Hori-
zontal bar indicates drug infusion.
(C) The glucose infusion rate needed to maintain
glycemia after drug infusion was significantly
larger in NBQX-treated mice (red bars, n = 7)
than in saline-treated mice (black bars, n = 5).
*p < 0.05 by Student’s t test.
(D) Proposed model for the regulation of glucagon
secretion. Activation of a cells depends on an ini-
tial stimulus as well as on positive feedback.
When glucose levels fall, there is less suppression
from b cell-derived GABA, Zn2+, or insulin. Positive
feedback by glutamate strongly amplifies gluca-
gon secretion. Once glucose levels increase, glu-
cagon secretion is inhibited by insulin, Zn2+,
GABA, or a combination of the three. Without glu-
tamate feedback, a cells are not fully activated and
glucagon secretion is deficient.hands, for instance, islet cell immunostaining with antibodies
recognizing the AMPA receptor subunits GluR2 and GluR3 was
not specific—that is, it could not be blocked by peptide pread-
sorption of the antibody. Because of the modest effects of gluta-
mate receptor ligands on insulin secretion and the low incidence
of glutamate-responsive b cells in previous studies, authors have
hesitated to ascribe a major functional role to glutamate recep-
tors in the regulation of insulin secretion (Molnar et al., 1995).
This is in line with our single-cell RT-PCR results showing that
b cells did not express iGluRs. Our findings showing that b cell
activity and insulin secretion could not be stimulated with gluta-
mate receptor agonists further strongly suggest that glutamate
signaling and in particular iGluRs are not involved in the regula-
tion of insulin secretion.
To be relevant for paracrine or autocrine signaling, glutamate
must be released from islet cells in response to physiological
stimulation. Studies using rodent islets have shown that a cells
express vesicular glutamate transporters that facilitate gluta-
mate uptake into secretory vesicles (Hayashi et al., 2001) and
that glutamate is present in glucagon secretory granules and is
coreleased with glucagon (Hayashi et al., 2003c). In the present
study, we found that human and monkey a cells express thevesicular glutamate transporter vGluT1. We detected glutamate
secretion in response to specific stimulation of a cells, confirm-
ing that a cells are a major source of glutamate in primate islets.
Although neurons or nerve terminals could also release gluta-
mate, our results were obtained using cultured isolated islets
that did not contain neuronal elements (see also Karlsson
et al., 1997). Because we found that a cells secrete glutamate
and because iGluRs were exclusively expressed in a cells, the
most likely scenario is that glutamate is an autocrine signaling
molecule. Our results showing that blockade of iGluRs dimin-
ishes the glucagon response to a lowering in glucose concentra-
tion (see Figure 5) indicate that glutamate is endogenously
released and corroborate that glutamate signaling provides
a positive autocrine feedback loop.
The notion of an autocrine loop with positive feedback helps
explain how a cells respond appropriately to a lowering in
plasma glucose concentration. By using the hypoglycemic
clamp in mice, we stimulated glucagon secretion in vivo and
found that glucagon response was significantly diminished by
pharmacological blockade of iGluRs. In these mice, hypoglyce-
mia was exacerbated, indicating that iGluRs need to be acti-
vated for a full glucagon response in the context of glucoseCell Metabolism 7, 545–554, June 2008 ª2008 Elsevier Inc. 551
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effects that glutamate may have on central and peripheral neu-
rons that could indirectly affect a cells, our in vitro data demon-
strate that the a cell is a major direct target for glutamate and that
intraislet glutamate signaling may function independently of ner-
vous input. Therefore, the most straightforward interpretation
of our results is that the glutamate autocrine feedback loop is
activated in a cells to potentiate glucagon secretion.
We now put forward a model that at least in part explains how
glucagon release can be effectively regulated in human pancre-
atic islets (Figure 7D). When there is a lowering in blood glucose
concentration, the negative paracrine influence of b cells on
a cells decreases (the ‘‘switch-off’’ hypothesis; Cryer et al.,
2003; Hope et al., 2004; Zhou et al., 2004). At this stage, the glu-
cose concentration is too low to inhibit (MacDonald et al., 2007;
MacDonald and Rorsman, 2007) but still high enough to drive
(Olsen et al., 2005) partial glucagon release and in parallel gluta-
mate release, creating a positive feedback loop through iGluRs
that potentiates a cell secretory activity. This is in agreement
with our results showing that pharmacological blockade of
iGluRs exacerbates insulin-induced hypoglycemia and reduces
glucagon secretion in vivo. An interesting possibility is that in
the absence of functional b cells, there is chronic release of glu-
tamate, desensitizing a cell iGluRs. This may explain the lack of
effective glucose counterregulation in individuals with diabetes.
EXPERIMENTAL PROCEDURES
Islet Isolation and Culture
Human (n = 12, age = 48 ± 7 years), monkey (Macaca fascicularis; n = 15; age >
4 years), and young adult mouse (C57BL/6; n = 15) islets were isolated and cul-
tured as described elsewhere (Cabrera et al., 2006). Mutant mice lacking the
metabotropic glutamate receptor mGluR4 (C57BL/6 background) were
purchased from The Jackson Laboratory. All experimental protocols using
monkeys and mice were approved by the University of Miami Animal Care
and Use Committee.
Determination of Cytoplasmic Free Ca2+
Imaging of [Ca2+]i was performed as described elsewhere (Cabrera et al.,
2006). Islets or dispersed islet cells were immersed in HEPES-buffered solu-
tion (in mM: 125 NaCl, 5.9 KCl, 2.56 CaCl2, 1 MgCl2, 25 HEPES; 0.1% BSA
[pH 7.4]). Glucose was added to yield a final concentration of 3 mM. Islets or
dispersed islet cells were incubated in Fura-2 AM (2 mM) for 1 hr and placed
in a closed small-volume imaging chamber (Warner Instruments). Stimuli
were applied with the bath solution. Islets loaded with Fura-2 were excited
alternately at 340 and 380 nm with a Cairn Research Optoscan Monochroma-
tor light source. Images were acquired with a Hamamatsu camera attached to
a Zeiss Axiovert 200 microscope. Changes in the 340/380 fluorescence emis-
sion ratio over time were analyzed in individual islets and dispersed cells using
Kinetic Imaging AQM Advance software. Peak changes in the fluorescence
ratio constituted the response amplitude.
Dynamic Measurements of Glucagon and Insulin Secretion
A high-capacity, automated perifusion system was developed to dynamically
measure hormone secretion from pancreatic islets. A low-pulsatility peristaltic
pump pushed HEPES-buffered solution (in mM: 125 NaCl, 5.9 KCl, 2.56 CaCl2,
1 MgCl2, 25 HEPES; 0.1% BSA [pH 7.4]) at a perifusion rate of 100 ml/min
through a column containing 100 pancreatic islets immobilized in Bio-Gel
P-4 Gel (Bio-Rad). Except where stated otherwise, glucose concentration
was adjusted to 3 mM for all experiments. Stimuli were applied with the peri-
fusion buffer. The perifusate was collected in an automatic fraction collector
designed for a 96-well plate format. The columns containing the islets and
the perifusion solutions were kept at 37C, and the perifusate in the collecting
plate was kept at <4C. Perifusates were collected every minute. Hormone552 Cell Metabolism 7, 545–554, June 2008 ª2008 Elsevier Inc.release in the perifusate was determined with the human or mouse Endocrine
LINCOplex Kit (Linco Research) following the manufacturer’s instructions.
Real-Time Determination of Glucagon Release with Biosensor Cells
HEK293H-CNG cells stably expressing human glucagon receptor (glucagon
biosensor cells) (BD Biosciences) were used to measure glucagon release in
real time. The BD ACTOne technology (BD Biosciences) uses a modified cyclic
nucleotide-gated (CNG) ion channel as a biosensor of cAMP activity in live
cells, allowing the fluorescent detection of Gs-coupled receptor activities.
The CNG channel colocalizes with adenylate cyclases on the plasma mem-
brane and opens when the cAMP level near the plasma membrane increases
subsequent to activation of the human glucagon receptor. The influx of Ca2+
through the CNG channel is quantified using fluorescent Ca2+ indicators.
Glucagon elicited concentration-dependent [Ca2+]i increases in glucagon
biosensor cells that were detectable at 10 pM and saturated at 300 pM.
Glucagon biosensor cells were grown in DMEM supplemented with FBS
(10%; Invitrogen), puromycin (10 mg/ml; BD Biosciences), and G418 sulfate
(500 mg/ml; Mediatech). Glucagon biosensor cells were loaded with Fura-2
AM (2 mM) for 30 min at 37C. After washing off excess Fura-2 AM, pancreatic
islets were placed on top of the glucagon biosensor cells and mounted in
a closed small-volume imaging chamber (Warner Instruments) to measure
[Ca2+]i as described above. Perifusion of the islets was stopped after addition
of the stimulus to allow the islet secretory products to accumulate and then
resumed after 10 min. The glucagon response profiles of the islets obtained
with this technique resembled those obtained in perifusion studies (compare
Figure 1 and Figure 6), but the biosensor cell assay was more sensitive and
showed less variability.
Microfluorometric Determination of Endogenous
Glutamate Release
Endogenous glutamate release from pancreatic islets was measured with the
Amplex Red Glutamic Acid Assay Kit (Molecular Probes) adapted for micro-
scopic microfluorometric detection (Akagi et al., 2003). In this assay, released
glutamate is a substrate in an enzymatic chain reaction that generates the
highly fluorescent product resorufin. L-glutamate is oxidized by glutamate
oxidase to produce a-ketoglutarate, NH4, and H2O2. Hydrogen peroxide
reacts with the Amplex Red reagent in a reaction catalyzed by horseradish per-
oxidase to generate resorufin. Pancreatic islets were allowed to attach to
a glass coverslip previously coated with poly-D-lysine. The coverslip was
mounted in a closed small-volume imaging chamber (Warner Instruments)
and perifused with the HEPES-buffered solution containing the stimuli. Resor-
ufin fluorescence was excited at 510 nm, and the emission was recorded at
590 nm using the same imaging system used to measure [Ca2+]i (see above).
Patch-Clamp Electrophysiology
Membrane currents were measured using whole-cell patch-clamp recordings
of dispersed human islet cells. All recordings were amplified using an EPC10
patch-clamp amplifier and digitized and analyzed using Patchmaster software
(HEKA Elektronik). Pipettes were pulled from borosilicate glass capillaries on
a horizontal programmable puller (DMZ Universal Puller, Zeitz-Instrumente).
Pipettes with a resistance of 5–7 MUwere filled with a pipette solution contain-
ing (in mM) 150 N-methyl-D-glucamine (NMG), 10 EGTA, 1 MgCl2, 2 CaCl2,
5 HEPES, and 3 MgATP (pH 7.15). The bath solution contained (in mM)
138 NaCl, 5.6 KCl, 1.2 MgCl2, 2.6 CaCl2, 5 HEPES, and 10 tetraethylammo-
nium (pH 7.4). Cells were voltage clamped at 70 mV. Ligands (e.g., kainate)
were applied using the SF-77B Perfusion Fast-Step system (Warner Instru-
ments), which allows rapid change of solutions bathing a single cell or mem-
brane patch attached to a patch electrode. We did not attempt to identify
cell type based on electrophysiological characterization because >75% of
the kainate-responsive cells in our [Ca2+]i imaging experiments were gluca-
gon-immunoreactive cells. Thus, it is most likely that the cells responding to
kainate in our electrophysiological experiments were a cells.
RT-PCR
Total RNA from >90% pure human and monkey islets was isolated using the
QIAGEN RNeasy Kit. cDNA was synthesized from 500 ng of total RNA using
the Invitrogen SuperScript First-Strand Synthesis System. cDNA (2 ml) was
used without further purification for PCR reaction (35 cycles) with a LightCycler
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and KA2) and vesicular glutamate transporters (vGluT1–3) were purchased
from QIAGEN and used at the concentrations suggested by the vendor.
Single-Cell RT-PCR
Human or monkey islets were dispersed into individual cells. Single cells were
harvested using glass micropipettes (20 mm) and placed in centrifuge tubes.
mRNA was reverse transcribed using the Invitrogen SuperScript First-Strand
Synthesis System. Real-time PCR was performed using TaqMan Fast Univer-
sal PCR Master Mix and the 7500 or 7900HT Fast Real-Time PCR System
(Applied Biosystems). The TaqMan assays were chosen to span an exon junc-
tion and therefore did not detect genomic DNA. Each cDNA was first amplified
with TaqMan probes specific for insulin, glucagon, somatostatin, and pancre-
atic polypeptide. Cells exclusively expressing one of the pancreatic hormones
were used for further PCR to detect the glutamate receptor units GRIA1–4
(AMPA receptor subunits) and GRIK1–5 (kainate receptor subunits) and the
metabotropic glutamate receptors 4 and 5 (GRM4 and GRM5).
Immunofluorescence
Immunofluorescence procedures were performed as described elsewhere
(Cabrera et al., 2006). Blocks of human, monkey, or mouse pancreas (0.5 cm3)
or isolated islets were fixed in 4% paraformaldehyde for 4–6 hr and frozen.
Sections (14 mm) were cut on a cryostat. After a rinse with OptiMax Wash
Buffer (Biogenex), sections were incubated in Universal Blocker Reagent
(Biogenex) for 5–10 min, rinsed again in OptiMax Wash Buffer, and incubated
in Protein Block (Biogenex) for 20 min. Thereafter, sections were incubated
overnight with anti-insulin (1:500; Accurate Chemical & Scientific Corp.),
anti-glucagon (1:2,000; Sigma), anti-somatostatin (1:500; Serotec), and
anti-pancreatic polypeptide (1:100; Serotec) antibodies. To visualize vesicular
glutamate transporters, sections were incubated in anti-vGluT1 (1:20,000;
Chemicon), anti-vGluT2 (1:10,000; Chemicon), or anti-vGluT3 (1: 20,000;
Chemicon) together with antisera against insulin and glucagon. To visualize
neuronal elements, isolated human islets were immunostained by applying
rabbit anti-synapsin 1/2 (1:500; Synaptic Systems), mouse anti-neuron-spe-
cific enolase (1:500; Chemicon), rabbit anti-neurofilament 200 (1:100; Sigma),
or chicken anti-neurofilament H (1:200; Neuromix). Immunostaining was visu-
alized using Alexa-conjugated secondary antibodies (1:400; Molecular
Probes). Cell nuclei were stained with DAPI (Molecular Probes). Slides were
mounted with ProLong Antifade (Molecular Probes) and coverslipped. As
a negative control, we substituted the primary antibody with the serum of
the animal used to raise that antibody. No staining was observed under these
conditions. Pancreatic sections containing islets were examined for expres-
sion of the different endocrine markers and vGluTs using a Zeiss LSM 510
scanning confocal microscope. We chose an optical section of 1 mm for all
image acquisitions. All images were digitally acquired and were not further pro-
cessed. Sections were viewed at 203 and 403 magnification. Digital images
were compiled using Adobe Photoshop 7.0. Only brightness and contrast
were adjusted.
In Vivo Studies
We examined in vivo responses to iGluR agonists by injecting C57BL/6 mice
i.p. with PBS (n = 4), monosodium glutamate (30 mg/kg; n = 7), or AMPA
(15 mg/kg; n = 8). To determine whether blocking iGluRs exacerbates insu-
lin-induced hypoglycemia, we injected the AMPA/kainate iGluR antagonist
NBQX (Tocris) i.p. at 20 mg/kg 30 min before mice were treated with insulin
to induce hypoglycemia.
Hyperinsulinemic-Hypoglycemic Clamp in Conscious Mice
To provide a standardized hypoglycemic stimulus, we further conducted stud-
ies using the hyperinsulinemic-hypoglycemic clamp. At least 4 days before the
experiments, mice were anesthetized with isoflurane, and an indwelling cathe-
ter was inserted in the left jugular vein and externalized through an incision in
a skin flap behind the head. Mice were fasted for 4 hr and placed in individual
plastic containers for tail cut sampling. Tail blood samples (20ml) were taken be-
fore the start of the experiment for determination of basal plasma glucagon and
insulin secretion. A priming dose of insulin (100 mU/kg) was administered, fol-
lowed by a constant infusion rate of 20 mU/kg/ min (Actrapid, Novo Nordisk).
The plasma glucose concentration was determined at 10 min intervals usinga OneTouch Ultra glucometer. Glucose (30%) was infused at a variable rate
to maintain the plasma glucose concentration at hypoglycemic levels
(3 mM). At 50 min, a hyperinsulinemic-hypoglycemic clamp was achieved.
Blood glucose levels were kept at the steady state (3 mM), and NBQX was
administered as a bolus (10 mg/kg) at 60 min followed by infusion (10 mg/kg)
until theend of theexperiment.A control experimentwas performed using saline
(0.9% NaCl) following the same protocol used for NBQX. Tail blood samples
(20 ml) were taken at 0, 50, 75, and 90 min for determination of plasma glucagon
and insulin secretion. Animals were euthanized by an overdose of pentobarbital.
Statistical Analyses
Statistical comparisons were performed using Student’s t test, one-way
ANOVA, or repeated-measures ANOVA followed by multiple-comparison
procedures with the Student-Newman-Keuls method.
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